Thanks for emailing that article!
The Catalyst for a Cure Biomarker Initiative funded by Glaucoma Research Foundation is a collaborative research effort designed to accelerate the pace of discovery toward better treatments and ultimately a cure for glaucoma.
The Catalyst for a Cure (CFC) principal investigators are: Alfredo Dubra, PhD, Medical College of Wisconsin; Jeffrey Goldberg, MD, PhD, Shiley Eye Center, University of California San Diego; Andrew Huberman, PhD, University of California San Diego; and Vivek Srinivasan, PhD, University of California Davis. This report from the CFC researchers summarizes findings as of February 2014.
Glaucoma is a leading cause of blindness worldwide. A major obstacle in the treatment and prevention of vision loss is the inability to detect the disease early, or to know which patients are at greater risk of losing vision. During the first 2 years of the collaboration, the Catalyst for a Cure team has identified several possible glaucoma biomarkers. In addition they have built a series of novel instruments for imaging the retina non-invasively that will be used to measure and test these new biomarkers.
The consortium of 4 research labs is highly collaborative, combining expertise in state of the art imaging, cellular and molecular biology, and clinical glaucoma. They are applying their expertise toward biomarker discovery with the direct goal of improving patient care.
Together, one or more of these approaches may yield highly sensitive biomarkers for glaucoma detection and progression, and provide a sensitive means to monitor treatment efficacy. The Catalyst for a Cure team continues to work towards validation of these targets and technologies in models of glaucoma, and towards rapid translation into human testing.
First posted February 14. 2014. This report summarizes research findings as of February 2014.
Last reviewed on June 11, 2021